Lung cancer with EGFR mutation treatment study
Part of Cancer, Lungs & breathing clinical trials.
This study looks at real-world information from people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to understand how patients are treated and what outcomes they have, which may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that is advanced (stage IIIB or IV) and cannot be removed with surgery.
- Your cancer must have a specific gene change called an EGFR mutation.
- You must have been diagnosed and treated for your lung cancer at one of the participating study centers.
- Your diagnosis must have happened between July 2018 and March 2022.
- You must not have received cancer treatment outside of the participating centers.
- You must not have had any other cancer in the past 5 years, except for common skin cancers (basal cell or squamous cell carcinoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses leftover tissue or fluid from your lung cancer to test how it responds to different drugs in the lab. The goal is to understand which treatments might work best for tumors with EGFR mutations, which could help guide future treatment decisions.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This trial collects information from people with a specific type of advanced lung cancer to create a comparison group. It helps researchers understand how well new treatments work without giving any experimental medicine.
This trial is building a large database of lung cancer patients from Asia who have a specific EGFR mutation (exon 20 insertion). Your medical records and treatment information will be collected to help doctors learn more about this type of cancer and improve care.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.